Howlader A Hasan, Jiang Xuanhe, Zhou Zehui, Greenberg Marc M
Johns Hopkins University, Department of Chemistry, 3400 N. Charles St., Baltimore, Maryland 21218, United States.
J Org Chem. 2025 Sep 7. doi: 10.1021/acs.joc.5c01529.
Base excision repair (BER) is a DNA repair pathway responsible for protecting the genome against modified nucleotides. DNA polymerase β (Pol β) participates in this process by removing the remnants of a damaged nucleotide and filling in the resulting gap. Pol β is overexpressed in some cancers and is synthetic lethal in cells deficient in BRCA1/2, providing additional impetus for identifying inhibitors of this enzyme. We report noncovalent Pol β inhibitors that are nonnative nucleotides. The inhibitors were identified via a combination of structural and biochemical analysis, as well as serendipity, from an initial library of covalent inhibitor candidates in which diversity was introduced sequentially at the C3'- and C5-positions of pyrimidine nucleotides. The molecules are among the most potent Pol β inhibitors ( ≤ 70 nM) of the enzyme's polymerase and lyase activities. Kinetic analyses reveal that the molecules inhibit Pol β noncompetitively. Fluorescence anisotropy and kinetic experiments reveal that the more potent inhibitor binds in the lyase domain and does not prevent DNA binding. Neither the more potent noncompetitive inhibitor nor a neutral protide exhibits cytotoxic synergism with the DNA damaging agent methyl methanesulfonate in HeLa cells. Cell permeability experiments suggest that micromolar levels of the more potent noncompetitive inhibitor and corresponding protide are taken up by HeLa cells following 24 h incubation (25 μM). However, based upon a comparison with other molecules, it is possible that they are membrane bound. The molecules identified could be useful tools in biochemical studies and provide a starting point for creating new Pol β inhibitors that function in cells.
碱基切除修复(BER)是一种DNA修复途径,负责保护基因组免受修饰核苷酸的影响。DNA聚合酶β(Polβ)通过去除受损核苷酸的残余物并填补由此产生的缺口来参与这一过程。Polβ在某些癌症中过表达,并且在缺乏BRCA1/2的细胞中具有合成致死性,这为鉴定该酶的抑制剂提供了额外的动力。我们报道了非共价的Polβ抑制剂,它们是非天然核苷酸。这些抑制剂是通过结构和生化分析以及偶然发现,从一个共价抑制剂候选物的初始文库中鉴定出来的,在该文库中,嘧啶核苷酸的C3'-和C5-位依次引入了多样性。这些分子是该酶聚合酶和裂解酶活性最有效的Polβ抑制剂之一(≤70 nM)。动力学分析表明,这些分子以非竞争性方式抑制Polβ。荧光各向异性和动力学实验表明,更有效的抑制剂结合在裂解酶结构域中,并且不阻止DNA结合。在HeLa细胞中,更有效的非竞争性抑制剂和中性前药与DNA损伤剂甲磺酸甲酯均未表现出细胞毒性协同作用。细胞通透性实验表明,在24小时孵育(25μM)后,HeLa细胞摄取了微摩尔水平的更有效的非竞争性抑制剂和相应的前药。然而,基于与其他分子的比较,它们有可能是膜结合的。鉴定出的这些分子可能是生化研究中的有用工具,并为创建在细胞中起作用的新型Polβ抑制剂提供了一个起点。